tailieunhanh - Ebook Cannabis - A clinician’s guide: Part 2

(BQ) Part 2 book “Cannabis - A clinician’s guide” has contents: Cannabis in palliative care, what to expect at the cannabis dispensary, cannabis nutrition, commercial cultivation of cannabis, legal aspects of cannabis, quality assurance in the cannabis industry, and other contents. | chapter fourteen Clinical rationale for CBD use on mood, depression, anxiety, brain function, and optimal aging Chris D. Meletis and Betty Wedman-St. Louis Contents Brain function 140 Memory disorders. 140 CBD therapeutic considerations. 142 Harnessing the endocannabinoid system (ECS) 143 References 143 The astronomical growth in cannabis research can be seen in the 22,000 published studies or reviews in the scientific literature referencing the cannabis plant and its cannabinoids, with nearly 50% of them published within the past 10 years according to Pub Med Central, the . government repository for peer-reviewed scientific research [1]. According to the . Hemp Business Journal, hemp industry sales for food, body care, and CBD products grew to $688 million in 2016 and are estimated to top $800 million by 2020. Of the $688 million market was food at 19%, hemp CBD at 19%, supplements at 4%, personal care product at 24%, consumer textiles at 14%, industrial application at 18%, and other consumer products at 2% [2]. The growth of hemp CBD at $130 million in sales contributed significantly to the $688 million market. The CBD sales were in natural and specialty products, smoke shops, and on-line purchases. CBD-based pet care products, estimated at $2,470,000, is considered a definite growth category to watch [2]. Robson [3] details how cannabis has been a known medicine for several thousand years but has become mired in disrepute and legal controls in the